Cytomx Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytomx Therapeutics, Inc. on December 22, 2020, reporting events occurring on December 16, 2020. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
On December 16, 2020, Mani Mohindru, Ph.D., was appointed to the Board of Directors as a Class I director to fill a vacancy. His initial term expires at the 2022 annual meeting of stockholders.
Compensation and Governance Details
- Equity Grant: Dr. Mohindru received an option to purchase 40,000 shares of common stock under the 2015 Equity Incentive Plan.
- Exercise Price: Set at the closing price of the common stock on December 16, 2020.
- Vesting Schedule: The option vests monthly, with 1/36th of the shares becoming exercisable on each monthly anniversary of the appointment, contingent on continued service.
- Other Compensation: Dr. Mohindru will receive standard non-employee director compensation as outlined in the preliminary proxy statement filed on April 17, 2020.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Mohindru.
The Company confirmed there are no transactions exceeding $120,000 involving Dr. Mohindru since the beginning of the last fiscal year, nor any arrangements regarding his appointment other than those disclosed.
Investor Verification Checklist
- Verify the closing stock price on December 16, 2020, to determine the exercise price of the 40,000 share option.
- Review the preliminary proxy statement filed on April 17, 2020, for details on standard non-employee director cash compensation.
- Confirm the total number of shares authorized under the 2015 Equity Incentive Plan to assess the impact of this grant.
- Check subsequent filings for the formal ratification of Dr. Mohindru's appointment at the 2022 annual meeting.